Roche to Acquire Promedior for $1.39B
Shots:
- Promedior to receive $390M up front and up to $1B development- regulatory and commercial milestones- making the total deal value as $1.39B. Roche to get full rights for Promedior's fibrotic diseases portfolio including its lead asset PRM-151
- The acquisition will leverage Roche’s drug development capabilities and expertise to further advance PRM-151 in fibrotic diseases- including idiopathic pulmonary fibrosis and myelofibrosis
- Promedior’s PRM-151 is a recombinant form of human pentraxin-2 (PTX-2) protein- demonstrated both prevention and reversal of fibrosis and has received FDA’s breakthrough therapy designation for IPF in H1’19
Click here to read full press release/ article
Ref: PRNewswire | Image: Roche
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com